• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Revolutionizing the Future of Immunotherapy Design

Bioengineer by Bioengineer
May 30, 2025
in Cancer
Reading Time: 4 mins read
0
blank
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

blank

In a groundbreaking fusion of computational engineering and immunotherapy, Dr. Natasa Miskov-Zivanov, an assistant professor of electrical and computer engineering at the University of Pittsburgh, has been awarded the highly coveted Faculty Early Career Development (CAREER) Award from the National Science Foundation (NSF). Her project, titled “Artificial Intelligence-Driven Framework for Efficient and Explainable Immunotherapy Design,” embarks on a transformative journey to revolutionize the engineering of immune cells, specifically lymphocytes, to devise next-generation therapies against cancer. Armed with a $581,503 grant, Miskov-Zivanov’s research employs advanced artificial intelligence (AI) techniques intertwined with knowledge graphs to automate and optimize the discovery and design of immunotherapeutic agents.

Immunotherapy, particularly Chimeric Antigen Receptor (CAR) T cell therapy, has already redefined the landscape of hematologic cancers such as leukemia and lymphoma by harnessing the patient’s own immune cells to eradicate malignant cells. The process involves extraction of T cells, their genetic reprogramming with a synthetic receptor, and reinfusion into the patient’s bloodstream. Despite its seminal success against blood cancers, this modality faces formidable hurdles when applied to solid tumors. The tumor microenvironment’s complexity and the difficulty of CAR T cells to adequately recognize and penetrate solid masses call for novel receptor configurations and sophisticated cell engineering approaches.

The combinatorial explosion of possible CAR T cell designs, coupled with the growing wealth of accumulated experimental data and literature, presents a daunting analytical challenge. To tackle this, Miskov-Zivanov aims to build an AI-powered system capable of sifting through vast bodies of scientific literature and heterogeneous data repositories to integrate expert knowledge and raw experimental insights. This system will intelligently recommend superior therapeutic lymphocyte designs, including both CAR T cells and tumor-infiltrating lymphocytes (TILs), by synthesizing disparate sources of information into actionable engineering guidance.

.adsslot_VFiwRoJACM{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_VFiwRoJACM{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_VFiwRoJACM{width:320px !important;height:50px !important;}
}

ADVERTISEMENT

Drawing on her unique background as a computer engineer with extensive postdoctoral experience in computational and systems biology, Miskov-Zivanov emphasizes automation in a field traditionally dominated by labor-intensive manual processes. She envisions her computational framework as a catalyst that automates the complex tasks typically performed by biologists, thereby accelerating and refining the design cycle for immunotherapeutic cells. This aspiration springs from her conviction that the convergence of computation and biology can unveil novel pathways that manual curation might never reveal.

Building on her earlier NSF-funded EAGER award, which developed a prototype tool utilizing Natural Language Processing (NLP) to extract pertinent data from scientific texts, she now evolves the approach to incorporate state-of-the-art large language models (LLMs) and neural networks. This hybrid system will not only parse and analyze scientific papers but also interpret experimental datasets to conduct comprehensive in silico experiments. By simulating thousands of potential cell designs computationally, this framework will perform hypothesis-driven screening prior to laboratory validation.

A critical innovation in Miskov-Zivanov’s project lies in developing improved prompting techniques for AI models, enabling more precise and relevant extraction of meaningful data from the overwhelming corpus of biomedical literature. Instead of forcing researchers to navigate tens of thousands of papers, many irrelevant to their queries, the system will pinpoint high-impact insights and knowledge, distilling the essence of complex biological narratives. This capability could dramatically reduce time and resources consumed in immunotherapy research and design.

To represent and utilize the extracted knowledge efficiently, Miskov-Zivanov converts science-derived data into knowledge graphs (KGs)—structured semantic networks encoding relationships among biological entities like proteins, signaling pathways, and cellular behaviors. These KGs serve as a scaffolding layer upon which graph neural networks (GNNs) operate. GNNs, leveraging their prowess in modeling graph-structured data, analyze interconnections within the KGs to predict the efficacy of various immunotherapeutic cell configurations. This synergistic blend amplifies predictive accuracy beyond what isolated datasets or traditional statistical models can achieve.

Understanding the imperative for educating emerging engineers in these frontier methodologies, Miskov-Zivanov has introduced a novel graduate-level course focused on knowledge graphs and their construction, interpretation, and application. She believes that equipping the next generation of researchers with computational tools capable of integrating structured knowledge and data-driven learning models is vital for addressing increasingly complex biomedical challenges. By nurturing interdisciplinary expertise, this educational initiative seeds future innovation in synthetic biology and therapeutic design.

Underlying this ambitious technological endeavor is the goal to establish a reliable methodology for engineering and systematically testing thousands of immunotherapeutic cell designs with diverse receptor systems. Success could catalyze breakthroughs in developing cellular therapies that effectively infiltrate and neutralize solid tumors—an enduring challenge in oncology. Moreover, the project aspires to contribute novel algorithmic innovations to identify, present, and validate trustworthy predictive data in biomedical research.

Reflecting on her motivation, Miskov-Zivanov shares a poignant narrative of how a childhood news story about a young leukemia patient cured by immunotherapy ignited her passion. Her dual lens as a computer engineer and a scientifically curious individual fuels her drive to forge impactful applications of computing technologies in life-saving medical research. Her work epitomizes the compelling convergence of artificial intelligence and biotechnology, promising to reshape cancer treatment paradigms.

Her department chair, Alan George, lauds her as a rising star and innovator whose research lab, the MeLoDy (Mechanisms and Logic of Dynamics) Laboratory, bridges digital circuits, synthetic biology, AI, and dynamic systems. The award spotlights Miskov-Zivanov’s pioneering approach to designing immunotherapies and teaching complex computational methods, setting the stage for profound future contributions in science and engineering.

Dr. Miskov-Zivanov’s project embodies the forefront of biomedical innovation, where AI-powered automation intersects with molecular engineering to tackle the enduring challenge of cancer therapy. By weaving together computational linguistics, graph theory, machine learning, and synthetic biology, she charts a new course toward more efficient, interpretable, and impactful immunotherapy design. The convergence of these fields promises to accelerate discovery and ultimately transform patient outcomes in oncology.

Subject of Research: Artificial Intelligence-driven design of immunotherapy cells, focusing on CAR T cells and tumor-infiltrating lymphocytes.

Article Title: Artificial Intelligence-Driven Framework Poised to Revolutionize Immunotherapy Design

News Publication Date: Not specified in the provided content.

Web References:

Natasa Miskov-Zivanov Faculty Page
NSF Award Detail
Pitt News on NSF EAGER Award
MeLoDy Laboratory

Keywords: Cancer immunotherapy, Generative AI, Computer science, Artificial intelligence, Deep learning, Systems neuroscience, T lymphocytes, Immune system

Tags: advanced receptor configurationsArtificial Intelligence in Medicineautomated immunotherapy optimizationcancer treatment breakthroughsCAR T cell therapy advancementscomputational biology applicationsimmunotherapeutic agent discoveryimmunotherapy designlymphocyte engineering innovationsNational Science Foundation CAREER awardsolid tumor challengestransformative medical research

Share12Tweet8Share2ShareShareShare2

Related Posts

New Alliance Launches Clinical Trials of Targeted Therapies for Rare Adrenal Cancers

October 23, 2025

Illuminating Life: Rice Scientists Create Glowing Sensors to Monitor Cellular Changes in Real Time

October 23, 2025

Study Reveals Hidden Immune Defense Mechanism That Could Combat Cancer

October 23, 2025

Mayo Clinic Partners in Groundbreaking Study Demonstrating Enhanced Survival Rates for Early Breast Cancer Patients

October 23, 2025

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1277 shares
    Share 510 Tweet 319
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    308 shares
    Share 123 Tweet 77
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    167 shares
    Share 67 Tweet 42
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    132 shares
    Share 53 Tweet 33

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Exploring Vicarious Trauma in Hospice Nurses

Assessing Muscularity Overvaluation and Eating Disorder Risks

Innovative ‘Molecular Dam’ Prevents Energy Loss in Nanocrystals

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 66 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.